Tuberculosis screening in patients starting antiretroviral therapy in sub-Saharan Africa: stretching diagnostics to the limits.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study.PLoS medicine · 2011
   Trial
2. Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis.The Journal of infectious diseases · 2011
   Review
3. Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance.Future microbiology · 2011
   Review
4. Pathogenesis and prevention of immune reconstitution disease during antiretroviral therapy.Expert review of anti-infective therapy · 2011
   Review

Corrections and comments

• Comment on
  Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa.2010

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as